7048-38-6

Usage

Uses

Used in Pharmaceutical Industry:
(5-CHLORO-2-METHOXYPHENYL)ACETONITRILE is used as an intermediate in the synthesis of various pharmaceuticals for its ability to contribute to the development of new drugs with specific therapeutic properties. Its unique structure allows for the creation of molecules with targeted effects on biological systems.
Used in Agrochemical Industry:
In the agrochemical industry, (5-CHLORO-2-METHOXYPHENYL)ACETONITRILE is used as a precursor in the production of agrochemicals, such as pesticides and herbicides. Its role in these applications is to provide a foundation for the creation of compounds that can effectively control, repel, or kill unwanted organisms in agricultural settings.
Used in Chemical Research:
(5-CHLORO-2-METHOXYPHENYL)ACETONITRILE is also utilized in chemical research as a starting material for the exploration of new chemical reactions and the synthesis of novel compounds. Its reactivity and structural features make it a valuable component in advancing scientific understanding and innovation in the field of chemistry.

InChI:InChI=1/C9H8ClNO/c1-12-9-3-2-8(10)6-7(9)4-5-11/h2-3,6H,4H2,1H3

Upstream product

• 7035-11-2 4-chloro-2-chloromethyl-1-methoxy-benzene 
• 151-50-8 potassium cyanide 
• 143-33-9 sodium cyanide 
• 623-12-1 4-chloromethoxybenzene 
• 7035-10-1 (5-chloro-2-methoxyphenyl)methanol 
• 33924-48-0 methyl 5-chloro-2-methoxybenzoate 
• 773837-37-9 sodium cyanide 
• 7035-09-8 5-chloro-2-methoxybenzaldehyde 
• 635-93-8 5-chlorosalicyclaldehyde 

Downstream Products

• 7569-62-2 (5-chloro-2-methoxy-phenyl)-acetic acid 
• 7048-28-4 2-<γ>Pyridyl-5-chloro-benzofuran 
• 7569-72-4 2-(5-chloro-2-methoxy-phenyl)-ethylamine 
• 7556-38-9 1-Cyano-1-<2-methoxy-5-chlor-phenyl>-3-dimethylamino-propan 
• 24161-38-4 5-chloro-2-hydroxyphenylacetic acid 
• 76322-41-3 ethyl (5-chloro-2-hydroxyphenyl)acetate 
• 76322-42-4 (5-Chloro-2-ethoxycarbonylmethoxy-phenyl)-acetic acid ethyl ester 
• 7569-63-3 (5-chloro-2-methoxyphenyl)acetyl chloride 
• 7556-39-0 2-(5-Chlor-2-methoxyphenyl)-N⁴,N⁴-dimethyl-1,4-butandiamin 
• 7569-69-9 (2-Methoxy-5-chlor-phenyl)-aethanol 
• 7593-00-2 <2-Methoxy-5-chlor-phenyl>-aethylchlorid 
• 14613-38-8 <2-Methoxy-5-chlor-phenyl>-aethylbromid 
• 7569-64-4 2-(5-chloro-2-methoxyphenyl)-N-methylacetamide 
• 7569-65-5 N-Aethyl-<2-methoxy-5-chlor-phenyl>-acetamid 

Relevant academic research and scientific papers

Discovery of Clinical Candidate 4-[2-(5-Amino-1H-pyrazol-4-yl)-4-chlorophenoxy]-5-chloro-2-fluoro-N-1,3-thiazol-4-ylbenzenesulfonamide (PF-05089771): Design and Optimization of Diaryl Ether Aryl Sulfonamides as Selective Inhibitors of NaV1.7

A series of acidic diaryl ether heterocyclic sulfonamides that are potent and subtype selective NaV1.7 inhibitors is described. Optimization of early lead matter focused on removal of structural alerts, improving metabolic stability and reducing cytochrome P450 inhibition driven drug-drug interaction concerns to deliver the desired balance of preclinical in vitro properties. Concerns over nonmetabolic routes of clearance, variable clearance in preclinical species, and subsequent low confidence human pharmacokinetic predictions led to the decision to conduct a human microdose study to determine clinical pharmacokinetics. The design strategies and results from preclinical PK and clinical human microdose PK data are described leading to the discovery of the first subtype selective NaV1.7 inhibitor clinical candidate PF-05089771 (34) which binds to a site in the voltage sensing domain.

Cycloalkyl-substituted mesyl benzamide derivatives, and preparation method and medical application thereof

The invention relates to cycloalkyl-substitutedmesyl benzamide derivatives, and a preparation method and medical application thereof. The invention particularly discloses compounds disclosed as Formula (I) or pharmaceutically acceptable salts, stereoisomers, solvated compounds or prodrugs thereof, and a preparation method and application thereof. All the groups in the formula are defined in the specification.

SODIUM CHANNEL MODULATORS FOR THE TREATMENT OF PAIN AND DIABETES

Provided herein are sodium channel modulating Compounds, in particular NaV1.7 modulating compounds of Formula I or compounds of Formula I′: In particular, provided herein are processes for the preparation of, intermediates used in the preparation of, pharmaceutical compositions comprising, and therapeutic methods comprising administering such compounds. In particular, provided herein are compounds for the treatment of pain and diabetes.

SELECTIVE NAV1.7 INHIBITORS FOR THE TREATMENT OF DIABETES

Provided herein are methods for treating or preventing prediabetes or diabetes, or maintaining or lowering blood or plasma glucose or maintaining or lowering blood or plasma glycated hemoglobin comprising administering to a subject in need thereof a therapeutically effective amount of a compound selectively inhibiting NaVl.7. In particular, provided herein are processes for the preparation of and intermediates used in the preparation of compounds selectively inhibiting NaV1.7, such as the compounds of Formula (I) or compounds of Formula (I').

SODIUM CHANNEL MODULATORS FOR THE TREATMENT OF PAIN

Provided herein are sodium channel modulating Compounds, in particular NaV1.7 modulating compounds of Formula I: In particular, provided herein are processes for the preparation of, intermediates used in the preparation of, pharmaceutical compositions comprising, and therapeutic methods comprising administering such compounds. In particular, provided herein are compounds for the treatment of pain.

Piperazinyl CCR1 antagonists-optimization of human liver microsome stability

The synthesis, biological activity, and pharmacokinetic profile of CCR1 antagonists are described.

PIPERIDINE DERIVATIVES AND THEIR USE AS SELECTIVE INHIBITORS OF MIP-1ALPHA BINDING TO ITS RECEPTOR CCR1

A compound of the formula (I) wherein a, b, c R1, R2, R3, R4, R5, R6, R7, Q, W, Y, and Z are defined as above , useful as potent and selective inhibitors of MIP-1α (CCL3) binding to its receptor CCR1 found on inflammatory and immunomodulatory cells (preferably leukocytes and lymphocytes).

Methods of using piperazine derivatives

The present invention relates to compounds of the formula I and the pharmaceutically acceptable forms thereof; wherein X, Y, a, b, c, d, R1, R2, R3, R4 and R5 are as defined herein. Moreover, the present invention is also directed at pharmaceutical compositions comprising a compound of the formula I and a pharmaceutically acceptable carrier. Furthermore, the present invention is directed at methods of using the herein described compounds and compositions for treating or preventing a disorder or condition that can be treated or prevented by antagonizing the CCR1 receptor in a mammal.

Novel sulfonic acid derivatives

A compound of the formula or the pharmaceutically acceptable salt thereof; wherein X, Y, a, b, c, d, R1, R2, R3 and R5 are as defined above useful to treat inflammation and other immune disorders.